Galectin Therapeutics Inc GALT
We take great care to ensure that the data presented and summarized in this overview for GALECTIN THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GALT
View all-
Vanguard Group Inc Valley Forge, PA2.13MShares$4.93 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$3.61 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$2.73 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA863KShares$1.99 Million0.0% of portfolio
-
Commonwealth Equity Services, LLC483KShares$1.12 Million0.0% of portfolio
-
Wealthspire Advisors, LLC New York, NY398KShares$920,2430.01% of portfolio
-
Geneos Wealth Management Inc.353KShares$815,2790.04% of portfolio
-
State Street Corp Boston, MA251KShares$579,8420.0% of portfolio
-
Morgan Stanley New York, NY246KShares$568,4440.0% of portfolio
-
Northern Trust Corp Chicago, IL234KShares$541,1860.0% of portfolio
Latest Institutional Activity in GALT
Top Purchases
Top Sells
About GALT
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Insider Transactions at GALT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 23
2024
|
Kary Eldred |
BUY
Open market or private purchase
|
Direct |
500
+0.99%
|
$1,000
$2.6 P/Share
|
|
Oct 17
2024
|
Kevin D Freeman |
BUY
Open market or private purchase
|
Direct |
1,300
+3.6%
|
$2,600
$2.64 P/Share
|
|
Oct 16
2024
|
Kevin D Freeman |
BUY
Open market or private purchase
|
Indirect |
5,000
+5.88%
|
$10,000
$2.7 P/Share
|
|
Oct 16
2024
|
Kevin D Freeman |
BUY
Open market or private purchase
|
Direct |
5,000
+13.0%
|
$10,000
$2.7 P/Share
|
|
Aug 23
2024
|
Richard A. Zordani Jr. |
BUY
Open market or private purchase
|
Direct |
1,759
+5.2%
|
$3,518
$2.3 P/Share
|
|
Aug 23
2024
|
Richard A. Zordani Jr. |
BUY
Open market or private purchase
|
Indirect |
1,000
+33.33%
|
$2,000
$2.3 P/Share
|
|
Aug 22
2024
|
Richard A. Zordani Jr. |
BUY
Open market or private purchase
|
Direct |
741
+2.39%
|
$1,482
$2.3 P/Share
|
|
Jun 20
2024
|
Kevin D Freeman |
BUY
Open market or private purchase
|
Direct |
2,500
+8.07%
|
$5,000
$2.38 P/Share
|
|
Apr 30
2024
|
Richard A. Zordani Jr. |
BUY
Open market or private purchase
|
Indirect |
1,000
+50.0%
|
$3,000
$3.52 P/Share
|
|
Apr 24
2024
|
Joel Lewis President and CEO |
BUY
Open market or private purchase
|
Indirect |
1,000
+33.33%
|
$3,000
$3.39 P/Share
|
|
Apr 23
2024
|
James C Czirr > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,677
-0.06%
|
$11,031
$3.06 P/Share
|
|
Apr 22
2024
|
James C Czirr > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
21,323
-0.36%
|
$63,969
$3.06 P/Share
|
|
Apr 22
2024
|
Kevin D Freeman |
BUY
Open market or private purchase
|
Direct |
2,500
+8.78%
|
$5,000
$2.98 P/Share
|
|
Apr 09
2024
|
Kevin D Freeman |
BUY
Acquisition or disposition by will or laws
|
Indirect |
2,063
+10.25%
|
-
|
|
Mar 01
2024
|
Joel Lewis President and CEO |
SELL
Grant, award, or other acquisition
|
Direct |
152,584
-14.53%
|
$152,584
$1.96 P/Share
|
|
Jan 24
2024
|
Richard E Uihlein |
BUY
Grant, award, or other acquisition
|
Direct |
23,256
+0.23%
|
$23,256
$1.72 P/Share
|
|
Jan 16
2024
|
Kary Eldred |
BUY
Open market or private purchase
|
Direct |
900
+0.9%
|
$1,800
$2.09 P/Share
|
|
Dec 29
2023
|
Joel Lewis President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
11,606
+1.1%
|
$11,606
$1.66 P/Share
|
|
Dec 15
2023
|
Joel Lewis President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
12,042
+1.15%
|
$12,042
$1.6 P/Share
|
|
Nov 30
2023
|
Joel Lewis President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
9,880
+0.96%
|
$9,880
$1.95 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 34.9K shares |
|---|---|
| Open market or private purchase | 23.2K shares |
| Acquisition or disposition by will or laws | 2.06K shares |
| Grant, award, or other acquisition | 153K shares |
|---|---|
| Open market or private sale | 25K shares |